FDA ac­cepts one, de­lays an­oth­er; Da­ta, deals and dol­lars for slate of biotechs

The schiz­o­phre­nia and ma­jor de­pres­sive dis­or­der drug out of Ot­su­ka Phar­ma­ceu­ti­cal and Lund­beck is now un­der pri­or­i­ty re­view at the FDA for an­oth­er in­di­ca­tion.

The drug de­vel­op­ers said the reg­u­la­tor will de­cide whether to ex­pand the la­bel of br­ex­pipra­zole, mar­ket­ed as Rex­ul­ti for ap­proved in­di­ca­tions, to in­clude ag­i­ta­tion as­so­ci­at­ed with Alzheimer’s de­men­tia by May 10. The com­pa­nies said the FDA in­di­cat­ed it plans to con­vene an ex­pert pan­el to ad­vise on the ap­pli­ca­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER